Telix Pharmaceuticals Stock Leads 3 ASX Picks Trading Below Cash Flow Value

With Germany’s 10 year Bund yields sitting near multi year highs as investors focus on inflation and tighter policy risk, a lot of attention has shifted back to dependable cash flows and what investors are paying for them. That sets the stage for mispriced opportunities where discounted cash flow values and market prices do not line up. This article highlights three undervalued cash flow stocks from the SWS DCF screener that may warrant a closer look.

The three stocks highlighted below are just a sample from this idea, and the full screen surfaced 41 more companies with cash flow profiles and valuation gaps that may also interest value driven investors. To identify and analyze those opportunities in detail, head straight to the Undervalued Stocks Based On Cash Flows screener.

Telix Pharmaceuticals (ASX:TLX)

Telix Pharmaceuticals is a commercial stage biopharma company that develops and sells radiopharmaceuticals used to image and treat cancers, with its Illuccix imaging product and late stage TLX591 therapy at the center of its cash flow potential and link to the Undervalued Stocks Based On Cash Flows theme. Most revenue comes from the Precision Medicine segment at about $704 million, with Manufacturing Solutions contributing around $277 million, before internal adjustments. The company is relatively large for an ASX biotech, with a market cap of about A$5.5b.

Investors looking at Telix are essentially weighing an established and growing prostate cancer imaging franchise against a deep therapy pipeline that could reshape the company’s cash flows if late stage trials succeed. Illuccix and Gozellix already underpin meaningful revenue and EBITDA. In addition, Phase 3 programs such as ProstACT Global and TLX250-Tx carry the possibility of new treatment driven income. The catch is that Telix relies on external borrowing, carries only modest margins, and still has an SEC subpoena and trial risks hanging over the story. For investors focused on discounted cash flow value, this mix of current cash generation and pipeline optionality, set against very real funding and execution risks, is exactly where the opportunity may lie.

Telix’s cash flows depend on an established imaging business and an ambitious therapy pipeline that many investors may still be pricing cautiously. Get the full story in the 3 key rewards and 2 important warning signs (1 is major!)

Lynas Rare Earths (ASX:LYC)

Lynas Rare Earths is a rare earths miner and processor that extracts ore from the Mt Weld mine in Western Australia and upgrades it through concentration and advanced materials plants in Kalgoorlie and Gebeng in Malaysia. Its A$716 million in revenue comes from a single Rare Earth Operations segment, which turns elements such as neodymium and praseodymium into high purity products that tie directly into this cash flow focused screener theme. Lynas Rare Earths has a market cap of about A$16.5b.

Lynas Rare Earths is attracting interest because its Mt Weld and Gebeng operations connect a growing rare earth supply chain with a stock that SWS models as trading below DCF based fair value. Forecast revenue and earnings growth, plus improving margins and ROE, suggest meaningful cash flow potential if expansion and downstream processing plans keep on track. At the same time, a rich P/S multiple, reliance on external funding and exposure to policy and regulatory shifts, particularly in Malaysia, mean expectations are high and execution risk matters. For investors who want exposure to rare earths but also care about long term cash generation, that tension is exactly what makes Lynas worth a closer look.

Revenue, expansion plans and DCF value are starting to pull apart for Lynas Rare Earths. See how SWS joins that story to a full analysis report for Lynas Rare Earths and one underappreciated pressure point investors often miss.

WiseTech Global (ASX:WTC)

WiseTech Global develops cloud-based software that helps logistics providers manage the movement and storage of goods, with its CargoWise platform generating recurring subscription and services cash flows that link it directly to the undervalued cash flow theme. The company sells into logistics operators across the Americas, Asia Pacific and Europe, the Middle East and Africa, with revenue spread across these regions rather than tied to a single market. WiseTech Global has a market cap of about A$14.5b.

WiseTech Global may appeal to cash flow focused investors because CargoWise delivers long term recurring revenue from freight forwarders and customs brokers. Acquisitions like E2open are intended to widen that stream across the full supply chain. At the same time, the stock trades below SWS’s DCF estimate despite an earnings growth outlook that is described as ahead of the broader Australian market, which suggests a valuation gap if execution on integration and product rollout is successful. The flip side is the risk from higher leverage, an ACCC competition probe, and a shift to transaction based pricing that could pressure margins if volume growth does not keep pace. For investors willing to weigh those trade offs, WiseTech’s cash flow characteristics are not yet fully reflected in headline numbers.

WiseTech Global’s recurring cash flows and acquisition push are starting to decouple from where the market prices the stock. Get the full story in the 2 key rewards and 3 important warning signs (1 is major!)

Seeking Fresh Alternatives Beyond These Three

Some of the next breakout stocks are still flying under the radar for now. Screen them before the crowd, while it matters, and get in early.

• Hunt for cash rich compounders using a curated 10 high quality undervalued stocks that filters for quality balance sheets before momentum really builds.
• Track companies powering AI infrastructure growth through the focused 55 AI infrastructure stocks and spot potential winners before expectations run away from you.
• Target resilient balance sheets with the curated list of solid balance sheet and fundamentals (21 results) and find businesses that may hold up when weaker stocks start dropping.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com